Effects of Butylphthalide combined with Betahistine in treatment of patients with posterior circulation ischemic vertigo
Objective:To observe effects of Butylphthalide combined with Betahistine in treatment of patients with posterior circulation ischemic vertigo.Methods:A prospective study was conducted on 88 patients with posterior circulation ischemic vertigo admitted to this hospital from January 2022 to February 2023.They were divided into control group and study group according to the random number table method,44 cases in each.The control group was treated with Betahistine,while the study group was treated with Butylphthalide soft capsules on the basis of that of the control group.The clinical efficacy,the serological indexes[calcitonin gene-related peptide(CGRP),creatine kinase isoenzyme(CK-MB),brain natriuretic peptide(BNP)]levels before and after the treatment,the cerebral blood flow velocity[anterior cerebral artery(ACA),vertebrobasilar artery(BA)],the improvement of clinical symptoms[dizziness handicap inventory(DHI)score,vertigo disappearance time],and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of treatment in the study group was 93.18% (41/44),which was higher than 75.00% (33/44)in the control group,and the difference was statistically significant(P<0.05).The levels of CGRP,CK-MB and BNP in the two groups were lower than those before the treatment,those in the study group were lower than those in the control group,and the differences were statistically significant(P<0.05).The blood flow velocities of ACA and BA in the two groups were higher than those before the treatment,those in the study group were higher than those in the control group,and the differences were statistically significant(P<0.05).The disappearance time of vertigo in the study group was shorter than that in the control group,and the difference was statistically significant(P<0.05).The DHI scores of the two groups were lower than those before the treatment,that in the study group was lower than that in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Butylphthalide combined with Betahistine in the treatment of the patients with posterior circulation ischemic vertigo can improve the clinical efficacy,reduce the levels of serological indexes,accelerate the cerebral blood flow velocities,and promote the disappearance of vertigo symptoms.Moreover,it is superior to Betahistine treatment.
万方数据
维普
